CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS · Delayed Price · Currency is USD
0.0100
0.00 (0.00%)
Jan 17, 2025, 4:00 PM EST

CNBX Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Sep - Aug.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Nov '24 Aug '24 Aug '23 Aug '22 Aug '21 Aug '20 2019 - 2015
Cash & Equivalents
0.020.030.130.121.390.78
Upgrade
Cash & Short-Term Investments
0.020.030.130.121.390.78
Upgrade
Cash Growth
-78.76%-79.63%10.37%-91.52%78.30%-77.92%
Upgrade
Prepaid Expenses
000.090.080.20.15
Upgrade
Total Current Assets
0.020.030.220.21.590.93
Upgrade
Property, Plant & Equipment
--0.270.440.640.86
Upgrade
Long-Term Investments
---0.180.850.43
Upgrade
Total Assets
0.020.030.50.813.082.22
Upgrade
Accounts Payable
0.050.040.340.460.180.23
Upgrade
Accrued Expenses
-0.930.61---
Upgrade
Short-Term Debt
1.331.31.341.760.87-
Upgrade
Other Current Liabilities
1.160.240.220.220.220.22
Upgrade
Total Current Liabilities
2.542.512.522.441.270.45
Upgrade
Other Long-Term Liabilities
---0--
Upgrade
Total Liabilities
2.542.512.522.441.270.45
Upgrade
Common Stock
00000.010.01
Upgrade
Additional Paid-In Capital
22.4722.4722.2418.0317.0615.37
Upgrade
Retained Earnings
-24.99-24.95-24.26-20.55-16.83-13.63
Upgrade
Comprehensive Income & Other
---0.881.550.01
Upgrade
Shareholders' Equity
-2.51-2.48-2.02-1.631.811.76
Upgrade
Total Liabilities & Equity
0.020.030.50.813.082.22
Upgrade
Total Debt
1.331.31.341.760.87-
Upgrade
Net Cash (Debt)
-1.31-1.27-1.21-1.640.510.78
Upgrade
Net Cash Growth
-----33.83%-77.92%
Upgrade
Net Cash Per Share
-0.04-0.04-0.14-1.340.450.69
Upgrade
Filing Date Shares Outstanding
31.1131.1128.311.261.241.13
Upgrade
Total Common Shares Outstanding
31.1131.1122.611.261.241.13
Upgrade
Working Capital
-2.51-2.48-2.29-2.250.320.48
Upgrade
Book Value Per Share
-0.08-0.08-0.09-1.301.461.57
Upgrade
Tangible Book Value
-2.51-2.48-2.02-1.631.811.76
Upgrade
Tangible Book Value Per Share
-0.08-0.08-0.09-1.301.461.57
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.